What is the prognosis of secondary thrombocytosis?

Updated: Dec 24, 2018
  • Author: Koyamangalath Krishnan, MD, FRCP, FACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

In general, secondary thrombocytosis (reactive thrombocytosis) is a temporary laboratory anomaly that resolves when the primary causative condition is addressed.

The overall prognosis in patients with secondary thrombocytosis reflects that of the underlying associated condition. With certain disorders, however (eg, chronic obstructive pulmonary disease [COPD], [20] ovarian cancer [21] ), the presence of thrombocytosis indicates a worse prognosis than for patients with the disorder who do not have thrombocytosis. For example, Harrison et al reported that thrombocytosis was an independent risk factor for increased 1-year mortality after COPD exacerbations; however, patients with thrombocytosis who received antiplatelet therapy had significantly lower 1-year mortality. [20]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!